Galectin Therapeutics Narrows Losses Amid R&D Cuts, Secures New Funding

TL;DR

**GALT is burning less cash and got a lifeline from its chairman, but it's still a high-risk bet on future drug success with mounting debt.**

AI Summary

GALECTIN THERAPEUTICS INC. reported a net loss of $7.521 million for the three months ended June 30, 2025, a significant improvement from the $12.371 million net loss in the same period of 2024. For the six months ended June 30, 2025, the net loss was $17.152 million, down from $23.860 million in the prior year. This reduction in net loss was primarily driven by a substantial decrease in research and development expenses, which fell from $9.813 million in Q2 2024 to $3.261 million in Q2 2025, and from $17.867 million to $9.746 million for the six-month period. The company's cash and cash equivalents stood at $13.771 million as of June 30, 2025, down from $15.120 million at December 31, 2024. Total liabilities increased to $132.769 million from $120.565 million, largely due to an increase in borrowing and accrued interest under convertible lines of credit from a related party, which rose from $74.376 million to $88.150 million. The company also extended the maturity dates of its April 2021 and September 2021 convertible notes to September 30, 2026, and secured a new $10 million line of credit from Chairman Richard Uihlein on July 8, 2025, to fund operations through June 30, 2026.

Why It Matters

For investors, the significant reduction in net loss and R&D expenses, coupled with securing a new $10 million line of credit from Chairman Richard Uihlein, signals a concerted effort to manage cash burn and extend the company's operational runway through June 30, 2026. However, the continued reliance on related-party financing and the substantial increase in total liabilities, particularly convertible debt, introduce considerable financial risk. Employees might face uncertainty given the reduced R&D spending, potentially impacting future project scope. Customers and the broader market for fibrotic disease and cancer therapies will be watching for progress in their clinical trials, as the company's long-term viability hinges on successful drug development in a highly competitive biopharmaceutical landscape.

Risk Assessment

Risk Level: high — The company has operated at a loss since inception and had no revenues, indicating a high operational risk. As of June 30, 2025, the total stockholders' deficit was $(118.890) million, worsening from $(104.793) million at December 31, 2024. The company explicitly states "substantial doubt about the Company's ability to continue as a going concern exists," despite securing additional financing.

Analyst Insight

Investors should approach GALT with extreme caution, recognizing it as a highly speculative investment. While the reduced net loss and new line of credit offer a temporary reprieve, the company's long-term viability depends entirely on successful clinical trial outcomes and future capital raises. Monitor R&D progress closely and be aware of the significant dilution risk from convertible debt.

Financial Highlights

total Debt

$132.769M

net Income

-$7.521M

cash Position

$13.771M

Key Numbers

• $17.152M — Net Loss (6 months) (Decreased from $23.860M in prior year, showing improved financial performance.)
• $9.746M — R&D Expenses (6 months) (Significantly reduced from $17.867M in prior year, driving loss reduction.)
• $13.771M — Cash and Cash Equivalents (Available to fund future operations as of June 30, 2025.)
• $132.769M — Total Liabilities (Increased from $120.565M at December 31, 2024, indicating growing debt burden.)
• $88.150M — Related Party Convertible Lines of Credit (Increased from $74.376M, highlighting reliance on Chairman Uihlein.)
• $10M — New Line of Credit (Secured from Richard Uihlein on July 8, 2025, extending cash runway.)
• $(118.890)M — Total Stockholders' Deficit (Worsened from $(104.793)M, indicating negative equity.)
• 64,060,262 — Common Shares Outstanding (As of August 7, 2025, up from 63,157,235 at December 31, 2024, indicating dilution.)
• September 30, 2026 — Convertible Note Maturity Date (Extended for April 2021 and September 2021 notes, providing temporary relief.)

Key Players & Entities

• GALECTIN THERAPEUTICS INC. (company) — clinical stage biopharmaceutical company
• Richard Uihlein (person) — Chairman and provider of related-party debt financing
• The Nasdaq Stock Market (regulator) — exchange where GALT common stock is registered
• $13.771 million (dollar_amount) — cash and cash equivalents at June 30, 2025
• $17.152 million (dollar_amount) — net loss for the six months ended June 30, 2025
• $9.746 million (dollar_amount) — research and development expenses for the six months ended June 30, 2025
• $88.150 million (dollar_amount) — borrowing and accrued interest under convertible lines of credit from related party at June 30, 2025
• $10 million (dollar_amount) — new line of credit secured on July 8, 2025
• September 30, 2026 (date) — extended maturity date for April 2021 and September 2021 convertible notes

FAQ

Risk Factors

• Substantial Net Losses and Negative Equity [high — financial]: The company reported a net loss of $7.521 million for Q2 2025 and $17.152 million for the six months ended June 30, 2025. This has contributed to a total stockholders' deficit of $(118.890) million as of June 30, 2025, indicating a significant negative equity position.
• Increasing Debt and Reliance on Related Party Financing [high — financial]: Total liabilities increased to $132.769 million as of June 30, 2025, up from $120.565 million at December 31, 2024. A significant portion of this increase is due to related party convertible lines of credit, which grew from $74.376 million to $88.150 million, highlighting dependence on Chairman Richard Uihlein.
• Limited Cash Runway Despite New Credit Line [medium — financial]: Cash and cash equivalents stood at $13.771 million as of June 30, 2025. While a new $10 million line of credit was secured from Chairman Uihlein to fund operations through June 30, 2026, the company's ongoing net losses and substantial liabilities pose a risk to its long-term financial stability.
• Convertible Note Maturities and Potential Dilution [medium — financial]: The maturity dates for existing convertible notes have been extended to September 30, 2026. However, the conversion of these notes, along with potential future financings, could lead to significant dilution for existing shareholders, as evidenced by the increase in common shares outstanding from 63,157,235 to 64,060,262.
• Dependence on Research and Development Success [medium — operational]: The company's financial performance is heavily tied to the success of its research and development programs. While R&D expenses decreased significantly to $9.746 million for the six months ended June 30, 2025, from $17.867 million in the prior year, continued investment is necessary for pipeline advancement.

Industry Context

Galectin Therapeutics operates in the biotechnology sector, focusing on developing novel therapies. This industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies often rely on external financing and strategic partnerships to fund operations and clinical trials.

Regulatory Implications

As a clinical-stage biopharmaceutical company, Galectin Therapeutics is subject to stringent regulations from bodies like the FDA. Successful navigation of clinical trials, manufacturing standards, and marketing approvals are critical. Any delays or failures in regulatory processes can have severe financial and operational consequences.

What Investors Should Do

1. Monitor R&D expense trends and clinical trial progress.
2. Assess the sustainability of operations given the cash position and debt levels.
3. Evaluate the impact of related party financing and potential dilution.

Key Dates

• 2025-06-30: End of Q2 2025 — Reported net loss of $7.521 million, improved from $12.371 million in Q2 2024. Cash and cash equivalents stood at $13.771 million, with total liabilities at $132.769 million.
• 2025-07-08: New $10 million line of credit secured — Provided by Chairman Richard Uihlein to fund operations through June 30, 2026, extending the company's cash runway.
• 2026-09-30: Extended maturity date for convertible notes — Maturity dates for April 2021 and September 2021 convertible notes extended, providing temporary relief from immediate repayment obligations.

Glossary

Stockholders' Deficit

A negative stockholders' equity, meaning the company's liabilities exceed its assets. (Galectin Therapeutics has a substantial stockholders' deficit of $(118.890) million as of June 30, 2025, indicating negative net worth.)

Convertible Lines of Credit

Debt instruments that can be converted into equity under certain conditions, often with interest accrual. (The company has significant borrowings under convertible lines of credit, particularly from a related party, which increased to $88.150 million.)

Cash Runway

The amount of time a company can continue to operate before running out of cash, based on its current burn rate. (The new $10 million line of credit is intended to extend the company's cash runway through June 30, 2026.)

Dilution

The reduction in the ownership percentage of a shareholder due to the issuance of new shares. (An increase in outstanding common shares suggests potential dilution for existing shareholders.)

Year-Over-Year Comparison

Compared to the prior year, Galectin Therapeutics has significantly reduced its net losses, with Q2 2025 losses down from $12.371 million to $7.521 million, and six-month losses from $23.860 million to $17.152 million. This improvement is largely attributed to a substantial decrease in R&D expenses. However, total liabilities have increased, driven by related party debt, and the company's cash position has slightly declined, while its stockholders' deficit has widened, indicating a worsening equity situation.

Filing Documents

• ef20050513_10q.htm (10-Q) — 904KB
• ef20050513_ex31-1.htm (EX-31.1) — 14KB
• ef20050513_ex31-2.htm (EX-31.2) — 12KB
• ef20050513_ex32-1.htm (EX-32.1) — 8KB
• ef20050513_ex32-2.htm (EX-32.2) — 8KB
• 0001140361-25-031039.txt ( ) — 5616KB
• galt-20250630.xsd (EX-101.SCH) — 46KB
• galt-20250630_def.xml (EX-101.DEF) — 279KB
• galt-20250630_lab.xml (EX-101.LAB) — 446KB
• galt-20250630_pre.xml (EX-101.PRE) — 288KB
• galt-20250630_cal.xml (EX-101.CAL) — 29KB
• ef20050513_10q_htm.xml (XML) — 645KB

— FINANCIAL INFORMATION

PART I — FINANCIAL INFORMATION PAGE ITEM 1. Unaudited Condensed Consolidated Financial Statements (unaudited) Condensed Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024 2 Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2025 and 2024 3 Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2025 and 2024 4 Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders' Deficit for the Three and Six Months Ended June 30, 2025 and 2024 5 Notes to Unaudited Condensed Consolidated Financial Statements 7 ITEM 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 21 ITEM 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 29 ITEM 4.

Controls and Procedures

Controls and Procedures 30

— OTHER INFORMATION

PART II — OTHER INFORMATION ITEM 1.

Legal Proceedings

Legal Proceedings 30 ITEM 1A.

Risk Factors

Risk Factors 30 ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds 30 ITEM 3. Defaults Upon Senior Securities 30 ITEM 4. Mine Safety Disclosures 30 ITEM 5. Other Information 30 ITEM 6. Exhibits 30

SIGNATURES

SIGNATURES 32 1 Index GALECTIN THERAPEUTICS INC. CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) June 30, 2025 December 31, 2024 (in thousands) ASSETS Current assets: Cash and cash equivalents $ 13,771 $ 15,120 Prepaid expenses and other current assets 1,656 2,132 Total current assets 15,427 17,252 Other assets 175 243 Total assets $ 15,602 $ 17,495 LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' DEFICIT Current liabilities: Accounts payable $ 5,865 $ 5,656 Accrued expenses and other 4,846 8,204 Accrued dividends payable 63 63 Convertible notes payable and accrued interest, net of discounts – related party (Note 3) — 21,117 Derivative liabilities (Note 4) — 369 Total current liabilities 10,774 35,409 Convertible notes payable and accrued interest, net of discounts – related party (Note 3) 32,308 10,733 Derivative liabilities (Note 4) 1,537 47 Borrowing and accrued interest under convertible lines of credit, net of debt discount – related party (Note 9) 88,150 74,376 Total liabilities 132,769 120,565 Commitments and contingencies (Note 11) Series C super dividend redeemable convertible preferred stock; 1,000 shares authorized, 176 shares issued and outstanding at June 30, 2025 and December 31, 2024, redemption value: $ 8,018,000 , liquidation value: $ 1,760,000 at June 30, 2025 1,723 1723 Stockholders' equity (deficit): Undesignated stock, $ 0.01 par value; 20,000,000 shares authorized, 20,000,000 designated at June 30, 2025 and December 31, 2024, respectively — — Series A 12% convertible preferred stock; 1,742,500 shares authorized, 1,210,000 and 1,235,000 issued and outstanding at June 30, 2025 and December 31, 2024, respectively, liquidation value $ 1,210,000 at June 30, 2025 490 500 Common stock, $ 0.001 par value; 150,000,000 shares authorized at June 30, 2025 and December 31, 2024, 64,060,262 and 63,157,235 issu

View Full Filing

View this 10-Q filing on SEC EDGAR